Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 2-plattformstudie av nye immunterapikombinasjoner hos deltakere med tidligere ubehandlet, avansert/metastatisk ikke-småcellet lungekreft

6. november 2026 oppdatert av: GlaxoSmithKline

En fase 2, randomisert, åpen plattformstudie som bruker en masterprotokoll for å evaluere nye immunterapikombinasjoner hos deltakere med tidligere ubehandlet, lokalt avansert/metastatisk, programmert dødsligand 1-selektert ikke-småcellet lungekreft

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

351

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Cipoletti Rio Negro, Argentina, R8324CVE
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
        • GSK Investigational Site
      • Florida, Argentina, 1602
        • GSK Investigational Site
      • Mar del Plata, Argentina, 7600
        • GSK Investigational Site
      • San Juan, Argentina, J5402DIL
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
      • Wilrijk, Belgia, 2650
        • GSK Investigational Site
      • Barretos, Brasil, 14784-400
        • GSK Investigational Site
      • Porto Alegre, Brasil, 90610-000
        • GSK Investigational Site
      • São Paulo, Brasil, 01246-000
        • GSK Investigational Site
      • Vitória, Brasil, 29043-260
        • GSK Investigational Site
      • Abu Dhabi, De forente arabiske emirater
        • GSK Investigational Site
      • Abu Dhabi, De forente arabiske emirater, 51900
        • GSK Investigational Site
      • Oulu, Finland, 90220
        • GSK Investigational Site
      • Tampere, Finland, 33520
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
      • Vaasa, Finland, 65130
        • GSK Investigational Site
    • Florida
      • Plantation, Florida, Forente stater, 33322-5426
        • GSK Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87131
        • GSK Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • GSK Investigational Site
    • West Virginia
      • Morgantown, West Virginia, Forente stater, 26506
        • GSK Investigational Site
      • Bordeaux, Frankrike, 33076
        • GSK Investigational Site
      • Caen, Frankrike, 14033
        • GSK Investigational Site
      • Marseille, Frankrike, 13009
        • GSK Investigational Site
      • Quimper, Frankrike, 29107
        • GSK Investigational Site
      • Strasbourg, Frankrike, 67091
        • GSK Investigational Site
      • Athens, Hellas, 11528
        • GSK Investigational Site
      • Pylaia Thessaloniki, Hellas, 57001
        • GSK Investigational Site
      • Thessaloniki, Hellas, 54645
        • GSK Investigational Site
    • Attica
      • Athens, Attica, Hellas, 115 27
        • GSK Investigational Site
      • Chaïdári, Attica, Hellas, 124 62
        • GSK Investigational Site
    • Central Macedonia
      • Thessaloniki, Central Macedonia, Hellas, 570 10
        • GSK Investigational Site
    • Thessaly
      • Larissa, Thessaly, Hellas, 411 10
        • GSK Investigational Site
      • Avellino, Italia, 83100
        • GSK Investigational Site
      • Bergamo, Italia, 24125
        • GSK Investigational Site
      • Pisa, Italia, 57124
        • GSK Investigational Site
      • Verona, Italia, 37045
        • GSK Investigational Site
    • GE
      • Genova, GE, Italia, 16132
        • GSK Investigational Site
      • Chiba, Japan, 277-8577
        • GSK Investigational Site
      • Fukuoka, Japan, 812-8582
        • GSK Investigational Site
      • Hyōgo, Japan, 673-8558
        • GSK Investigational Site
      • Kanagawa, Japan, 241-8515
        • GSK Investigational Site
      • Osaka, Japan, 590-0197
        • GSK Investigational Site
      • Saitama, Japan, 350-1298
        • GSK Investigational Site
      • Guadajalara, Mexico, 44280
        • GSK Investigational Site
      • San Luis Potosí City, Mexico, 78209
        • GSK Investigational Site
      • Enschede, Nederland, 7512 KZ
        • GSK Investigational Site
      • Groningen, Nederland, 9728 NZ
        • GSK Investigational Site
      • Leeuwarden, Nederland, 8934 AD
        • GSK Investigational Site
      • Utrecht, Nederland, 3543 AZ
        • GSK Investigational Site
      • Lublin, Polen, 20-954
        • GSK Investigational Site
      • Prabuty, Polen, 82-550
        • GSK Investigational Site
      • Siedlce, Polen, 08-110
        • GSK Investigational Site
      • Guimarães, Portugal, 4835-044
        • GSK Investigational Site
      • Lisbon, Portugal, 1500-650
        • GSK Investigational Site
      • Lisbon, Portugal, 1998-018
        • GSK Investigational Site
      • Porto, Portugal, 4200-072
        • GSK Investigational Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • GSK Investigational Site
      • Badajoz, Spania, 06080
        • GSK Investigational Site
      • Barcelona, Spania, 08035
        • GSK Investigational Site
      • Las Palmas de Gran Canar, Spania, 35016
        • GSK Investigational Site
      • Madrid, Spania, 28041
        • GSK Investigational Site
      • Madrid, Spania, 28046
        • GSK Investigational Site
      • Madrid, Spania, 28027
        • GSK Investigational Site
      • Málaga, Spania, 29010
        • GSK Investigational Site
      • PamplonaNavarra, Spania, 28027
        • GSK Investigational Site
      • Valencia, Spania, 46026
        • GSK Investigational Site
      • Valencia, Spania, 46009
        • GSK Investigational Site
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • GSK Investigational Site
      • L'Hospitalet de Llobregat, Barcelona, Spania, 08907
        • GSK Investigational Site
      • Middlesbrough, Storbritannia, TS4 3BW
        • GSK Investigational Site
      • Wolverhampton, Storbritannia, WV10 0QP
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, Storbritannia, HA6 2RN
        • GSK Investigational Site
      • Incheon, Sør -Korea, 21565
        • GSK Investigational Site
      • Seoul, Sør -Korea, 03080
        • GSK Investigational Site
      • Seoul, Sør -Korea, 03722
        • GSK Investigational Site
      • Suwon Gyeonggi-do, Sør -Korea, 442-723
        • GSK Investigational Site
      • Cape Town, Sør-Afrika, 7570
        • GSK Investigational Site
      • Parktown, Sør-Afrika, 2193
        • GSK Investigational Site
      • Bangkok, Thailand, 10210
        • GSK Investigational Site
      • Chiang Mai, Thailand, 50200
        • GSK Investigational Site
      • Kho Hong Hat Yai, Thailand, 90110
        • GSK Investigational Site
      • Khon Kaen, Thailand, 40002
        • GSK Investigational Site
      • Pathum Thani, Thailand, 12120
        • GSK Investigational Site
      • Ankara, Tyrkia (Türkiye), 06800
        • GSK Investigational Site
      • Ankara, Tyrkia (Türkiye), 06680
        • GSK Investigational Site
      • Antalya, Tyrkia (Türkiye), 07070
        • GSK Investigational Site
      • Istanbul, Tyrkia (Türkiye), 34214
        • GSK Investigational Site
    • Atakum
      • Samsun, Atakum, Tyrkia (Türkiye), 55200
        • GSK Investigational Site
      • Berlin, Tyskland, 13125
        • GSK Investigational Site
      • Heidelberg, Tyskland, 69126
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • GSK Investigational Site
    • Schleswig-Holstein
      • Großhansdorf, Schleswig-Holstein, Tyskland, 22927
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Tyskland, 07747
        • GSK Investigational Site
      • Budapest, Ungarn, H-1121
        • GSK Investigational Site
      • Gyöngyös, Ungarn, 3200
        • GSK Investigational Site
      • Tatabánya, Ungarn, 2800
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
  • No prior systemic therapy for their locally advanced or metastatic NSCLC
  • Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
  • PD-L1-high (TC/TPS >= 50%) tumor
  • Measurable disease based on RECIST 1.1, as determined by the investigator
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Adequate Baseline organ function
  • Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

  • Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
  • Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
  • Received prior therapy with any immune checkpoint inhibitors
  • Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
  • Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
  • Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
  • Autoimmune disease or syndrome that required systemic treatment within the past 2 years
  • Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
  • Received any live vaccine <= 30 days prior to first dose of study intervention
  • Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  • History or evidence of cardiac abnormalities
  • Current unstable liver or biliary disease
  • Severe infection within 4 weeks prior to the first dose of study intervention
  • Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
  • Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
  • Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Pembrolizumab Monotherapy

Participants will be administered with pembrolizumab as monotherapy in a fixed dose.

Pembrolizumab will be administered.

Eksperimentell: Dostarlimab Monotherapy

Participants will be administered with dostarlimab as monotherapy in a fixed dose.

Dostarlimab will be administered

Andre navn:
  • GSK4057190
Eksperimentell: Substudy 1A

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A).

Belrestotug will be administered.

Andre navn:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navn:
  • GSK4057190
Eksperimentell: Substudy 1B

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B).

Belrestotug will be administered.

Andre navn:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navn:
  • GSK4057190
Eksperimentell: Substudy 1C

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C).

Belrestotug will be administered.

Andre navn:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navn:
  • GSK4057190
Eksperimentell: Substudy 2A

Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug

Belrestotug will be administered.

Andre navn:
  • EOS884448
  • GSK4428859A

Nelistotug will be administered.

Andre navn:
  • GSK6097608

Dostarlimab will be administered

Andre navn:
  • GSK4057190

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Antall deltakere med behandling av fremvoksende bivirkninger (TEAE) og alvorlige bivirkninger (SAE)
Tidsramme: Opptil 228 uker
Opptil 228 uker
Antall deltakere med Teaes eller SAE -er som fører til dosemodifikasjoner eller behandlingsoppsamling
Tidsramme: Opptil 228 uker
Opptil 228 uker

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. oktober 2022

Primær fullføring (Faktiske)

26. oktober 2026

Studiet fullført (Antatt)

6. desember 2027

Datoer for studieregistrering

Først innsendt

30. september 2022

Først innsendt som oppfylte QC-kriteriene

30. september 2022

Først lagt ut (Faktiske)

4. oktober 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 213824
  • 2021-005115-32 (EudraCT-nummer)
  • GALAXIES LUNG-201 (Annen identifikator: Study Identifier)
  • 2023 (U.S. NIH-stipend/kontrakt)
  • 2023-505057-40-00 (Registeridentifikator: CTIS (EU))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Tilgangskriterier for IPD-deling

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .